Antibiotic Susceptibility Patterns of Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase Pseudomonas aeruginosa Clinical Isolates. 2015

Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard

BACKGROUND Pseudomonas aeruginosa is known as an opportunistic pathogen responsible for nosocomial infections. Multidrug (MDR) resistance bacteria are considered as a worldwide issue. The current research goal to investigate the antibiotic susceptibility pattern in Extended Spectrum beta-lactamase and non Extended Spectrum beta-lactamase producing P. aeruginosa clinical isolates. METHODS A total of 76 P.aeruginosa clinical isolates were collected from Milad hospital in Tehran, Iran, during 8 months period in 2012. P.aeruginosa clinical isolates were subjected for ESBL production by phenotypic methods. The antibiotic susceptibility patterns were identified in ESBL and non-ESBL P. aeruginosa by MIC. RESULTS our results demonstrated that 76.3% (n =58) isolates were resistant to more than three antibiotics and classified as MDR. The majority of MDR strains were found in ESBL producer P. aeruginosa. ceftazidim as 3rd generation of cephalosporins, ciprofloxacin, Ticarcillin and aztreonam were found as a base for definition of MDR in the current research. The effectiveness antibiotics against ESBL and non-ESBL were meropenem and amikacin, respectively. CONCLUSIONS based on our knowledge obtained from results, both ESBL and non-ESBL P. aeruginosa were resistant to extended antibiotics and this is a major health care problem. On the other hand, MDR strains more identified in ESBL producer P .a eruginosa. Also, carabapenem resistance observed in non-ESBL producer strains. Hence, it is recommended that the MDR strains should be following up. the prescription of ceftazidim, ciprofloxacin, Ticarcillin and aztreonam should be limited.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug

Related Publications

Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
January 2006, Mikrobiyoloji bulteni,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
January 1999, Research in microbiology,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
September 2010, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
January 2008, Indian journal of pathology & microbiology,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
May 1996, International journal of antimicrobial agents,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
June 2024, Infection,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
May 2004, International journal of antimicrobial agents,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
September 2006, Antimicrobial agents and chemotherapy,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
May 1999, Antimicrobial agents and chemotherapy,
Mostafa Akbariqomi, and Sobhan Ghafourian, and Morovat Taherikalani, and Satar Mohammadi, and Iraj Pakzad, and Nourkhoda Sadeghifard
November 1996, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!